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Abstract: 
 
Langerhans-like dendritic cells (LLDC) express the high-affinity IgE receptor FcεRI form that 
lacks the β-chain, and may play an important role in allergic inflammation via production of IL-
16. Secretion of mediators by human mast cells and basophils is mediated through FcεRI and is 
decreased by coaggregating these receptors to the low-affinity IgG receptor, FcγRII. We used a 
recently described human Ig fusion protein(GE2), which is composed of key portions of the 
human γ1 and the human ε heavy chains, to investigate its ability to inhibit IL-16 production 
from FcεRI-positive Langerhans-like dendritic cells through coaggregation of FcγRII and FcεRI. 
Unstimulated LLDC-derived from CD14-positive monocytes from atopic donors were shown to 
express FcγRII, an ITIM-containing receptor, but not FcεRI or FcγRIII which are activating 
(ITAM) receptors. When passively sensitized with antigen-specific, human IgE and then 
challenged with antigen, LLDC were stimulated to produce IL-16. However, when FcεRI and 
FcγRII were coaggregated with GE2, IL-16 production was significantly inhibited. Exposure of 
LLDCs to GE2 alone did not induce IL-16 production. Our results further extend our studies 
demonstrating the ability of GE2 to inhibit FcεRI-mediated responses through coaggregation 
with FcγRIIB and at the same time show that human LDCC can be modulated in a fashion 
similar to mast cells and basophils. 
 
Keywords: Langerhans cell | Dendritic cells | IgE | Fc receptors | IL-16 
 
Article: 
 
Introduction 
 
Coaggregation of human basophil FcεRI and FcγRII by crosslinking receptor-bound IgE and 
IgG, respectively, inhibits basophil mediator secretion [1], [2]. We recently showed that a novel 
human bifunctional Fcε–Fcγ fusion protein (GE2) that binds to FcεRI and FcγRII is capable of 
inhibiting human FcεRI-α chain, transgenic rodent mast cells, and human basophil functional and 
biochemical responses in vitro and in vivo [3]. In addition to basophils, mast cells, and B cells, 
Langerhans cells have also been implicated in the afferent and efferent limbs of the allergic 
response. Thus, epidermal Langerhans cells (LC) are capable of uptake and presentation of 
allergen-IgE complexes via FcεRI [4]. In addition, crosslinking FcεRI on LC leads to release of 
IL-16 which particiates in allergic inflammation through a variety of mechanisms [5]. 
 
Since it is now recognized that β-chain-deficient FcεRI is variably expressed on LC [4], [6], it 
was important to determine if Langerhans-like dendritic cells (LLDC) also express the inhibitory 
receptor, FcγRII, as this receptor can inhibit mediator secretion in other cell types. We then 
examined the hypothesis that the bifunctional GE2, by coaggregating FcγRII with FcεRI, would 
downregulate important LDCC FcεRI-mediated responses. 
 
Here we used LLDC to test the expression of the various FcγRs and to determine if 
coaggregating FcεRI–FcγRII inhibits their production of IL-16. We demonstrated that these cells 
express only FcγRII (CD32) and not FcγRI or FcγRIII. We also provide the first evidence that 
LLDC FcεRI functional responses can be downregulated via FcγRII. Thus, in addition to its 
ability to block IgE production from human B cells and secretion from human mast cells and 
basophils, GE2 could also block inflammation through the inhibition of IL-16 production from 
dendritic cells, another key aspect in the chain of human allergic responses. 
 
Materials and methods 
 
Antibodies and reagents 
 
Anti-FcεRI-α subunit mAb 22E7 was a gift from Dr. J. Kochan. Nonspecific mouse IgG1 
(MOPC31C), and antiFcγRIII were from Sigma, (St Louis, MO). The anti-FcγRII mAbs AT10 
(IgG1; recognizing all FcγRII isoforms), the anti-FcγRIIa mAbs IV.3 (IgG1; recognizing 
FcγRIIa isoforms), and anti-FcγRI (anti-CD64; clone 32.2, IgG1) Abs were obtained from 
Medarex (Annendale, NJ). For Western blotting, anti-FcγRIIa (Ab260)- and FcγRIIb (Ab163)-
specific antibodies were obtained from Clark Anderson, (Columbus, OH). The chimeric human 
anti-4-hydroxy-3-nitrophenacety1 (NP) IgE Abs were from Serotec Ltd. (Oxford, England). To 
construct the human Fcγ-Fcε protein, the human IgE Fc region was attached to the IgG γ1 
constant region using a (Gly4Ser)3 flexible linker. The gamma-epsilon fusion protein (GE2) was 
expressed in cell culture supernatants and purified by using an anti-human IgE affinity column as 
described [3]. 
 
Generation of Langerhans cell-like dendritic cells 
 
Human Langerhans-like dendritic cells were generated from monocytes as described 
previously [6], [7]. Peripheral blood (100 ml) was obtained from atopic volunteers with approval 
from the Human Studies Committee at the Medical College of Virginia. Leukocytes were 
separated from red blood cells by centrifugation over Ficoll-Hypaque (1:1 v/v) at 350g for 20 at 
room temperature with no break. The leukocyte fraction was washed twice with PBS/BSA and 
the CD14+ monocytes were negatively selected using a kit from Stemcell Technologies as per 
the manufacture's instructions. The CD14+ cells were cultured for 6 days at a cell density of 3.0–
10 × 105cells/ml in culture medium (RPMI 1640 supplemented with 10% heat-inactivated FCS, 
10 mM Hepes, 2 mM l-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin) containing 
rhIL-4 (100 ng/ml; R&D Systems, Minneapolis, MN), rhGM-CSF (250 ng/ml; Biosource), and 
natural human TGF-β1 (10 ng/ml; Biosource). NP-specific IgE (1 μg/ml) was added to increase 
FcεRI expression [6]. Medium was replaced at Days 3–4. 
 
Flow cytometry 
 
Cells were recovered by centrifugation at 800g at 4°C, washed with PBS/BSA, and incubated for 
30 min at 4°C with a 1:500 dilution of normal human serum. The cells were washed and 
incubated with the indicated Abs (10 μg/ml) for 1 h at 4°C. After antibody labeling, the cells 
were washed and incubated with a 1:100 dilution of F(ab′)2-FITC-goat anti-mouse for 30 min at 
4°C. After 3 washes, cells were resuspended in 400 μl of PBS/BSA. The mean intensity 
fluorescence was determined for at least 10,000 cells using a flow cytometer. MOPC31C was 
used as negative controls. All experiments were performed in duplicate. 
 
Cell activation 
 
LLDC were suspended in fresh medium (without cytokines) and sensitized with 1 μg/ml of 
human anti-NP IgE overnight at 37°C in a 5% CO2incubator. The next morning, cells were 
incubated with or without different concentrations of GE2 (0–5 μg/ml), nonspecific IgE (PSIgE; 
5 μg/ml), or nonspecific IgG (5 μg/ml) for 2 h. Cells were washed once with HBSS− (Hanks' 
buffered saline solution without Ca2+ or Mg2+)[8] and resuspended to 0.5–1.1 × 106 cells/ml in 
prewarmed HBSS+ (HBSS with 1.4 mM CaCl2 and 1 mM MgCl2). Washed cells were activated 
by incubation at 37°C for 12 h with optimal concentrations of NP-BSA (15 μg/ml) at 37°C in a 
5% CO2 incubator followed by centrifugation at 150g at 4°C. Alternatively, GE2 (5 μg/ml) or 
nonspecific IgE (5 μg/ml) was added for at least 2 h before challenge with varying 
concentrations of NP-BSA. Supernatants were stored at −70°C. IL-16 was measured in the 
supernatants using a kit from Biosource, (Camarillo, CA). All experiments were performed in 
duplicate. 
 
Immunoprecipitation and immunobloting 
 
IgE-sensitized LLDC, with or without GE2, were activated as above. Preparation of cell lysates, 
immunoprecipitation, and Western blotting were as previously described [2], [3], [8]. 
 
Statistics 
 
IL-16 production in GE2-treated and nontreated cells was compared using the unpaired t test 
with Welch's correction (Graphpad Prism). 
 
Results 
 
LLCC express FcεRI and FcγRII 
 
We initially determined if LLDC expressed various FcγR receptors as potential binding sites for 
GE2 such that they would allow for coaggregation with FcεRI and subsequent downregulation of 
FcεRI-mediated activation. LLDC were generated from purified monocytes by a 6-day culture in 
IL-4, GM-CSF, and TGF-β1. Confirming previous studies [6], these cells expressed CD1a, E-
cadherin, CLA, but not FcγRI or FcγRIII (data not shown). As seen in Fig. 1A, LLDC clearly 
expressed both FcεRI and FcγRII. Expression of both receptors was detected on greater than 
90% of LLDC. 
 
 
Fig. 1. (A) LLDC express FcεRI and FcγRII. LLDC were incubated at 4°C with 22E7 or AT10 (10 μg/ml) followed 
by FITC-labeled goat anti-mouse IgG antibodies (unfilled). An irrelevant mouse IgG (MOPC) was substituted for 
the receptor Abs as a negative control (filled). (B) Lack of expression of FcγRIIa isoforms by LLDC. (Left panel) 
LLDC were incubated at 4°C with IV.3 (10 μg/ml) followed by FITC-labeled goat anti-mouse IgG antibodies 
(dashed line). An irrelevant mouse IgG (MOPC) was substituted for the receptor Abs as a negative control (solid 
line). For Western blotting (right panel), U937 and TH1 cells (as positive controls) or LLDC were lysed, and the 
clarified supernatants immunoprecipitated with anti-FcγRIIa or anti-FcγRIIb-specific Abs [28]. shows FcγRII 
immunoprecipitated from 8 × 106 cells. The results are representative of two separate experiments. 
 
There are multiple FcγRII isoforms, representing the products of three distinct genes. Further 
experiments were performed to investigate which FcγRII receptors are found on LLDC. We 
detected low expression of FcγRIIa using FACs and Western blotting (Fig. 1B). Thus, although 
low expression of FcγRIIa was detected, it appears FcγRIIb is the main Fcγ receptor expressed 
on LLDC. 
 
 
Fig. 2. FcγRII/FcεRI coaggregation inhibits FcεRI-mediated LLDC IL-16 production. (A) LLDC were incubated 
with anti-NIP IgE (1 μg/ml) for at least 1 day. Cells were washed and incubated with increasing concentrations of 
GE2, nonspecific IgE (5 μg/ml; PS), or nonspecific normal human IgG1 (5 μg/ml; nh) in Iscove's medium at 37°C in 
a 5% CO2 incubator. Cells were washed and challenged with 15 μg/ml of NP-BSA for 12 h and the supernatants 
assayed for IL-16 production. Results from two separate experiments, each done in duplicate, are shown with the 
standard error of the mean (±SEM). *Values significantly reduced (P < 0.05) when comparing cells challenged with 
or without GE2. In B IgE-sensitized cells were incubated for 2 h with GE2 (5 μg/ml) or nonspecific PSIgE in 
Iscove's medium at 37°C in a 5% CO2incubator. The cells were washed and incubated with or without varying 
concentrations of NP-BSA for 12 h, and IL-16 was measured in the supernatants. Results are represented as the 
standard error of the mean of three separate experiments (±SEM). *Values significantly reduced (P < 0.01) when 
comparing cells challenged with or without GE2. 
 
FcγRII/FcεRI coaggregation inhibits LLDC FcεRI-mediated IL-16 production 
 
Recent studies indicate that IL-16, a potential mediator of allergic disease [5], is released from 
LLDC after IgE/FcεRI activation [6]. Given that we had shown that LLDC express FcεRI and 
FcγRII, we wanted to examine whether coaggregating these receptors via the GE2 protein could 
inhibit IL-16 secretion. To test this hypothesis we sensitized LLDC with anti-NIP IgE, treated 
them with or without GE2, and then activated them with NIP-BSA for 12 h. LDCC secretion of 
IL-16 in the culture supernatant was then measured. As seen in Fig. 2A, GE2 inhibited IL-16 
production in a dose-dependent fashion with a maximal inhibition seen with 5 μg/ml (63% 
inhibition). The inhibition of IL-16 secretion was also observed at several concentrations of 
antigen stimulation. Levels of anti-NIP IgE/NIP-BSA-mediated IL-16 secretion were maximal 
when LDCC were cultured with 15 μg/ml NIP-BSA for 12 h (SEM 368 pg/105 cells; ± 13, n = 3) 
comparable to previous studies [6]. However, GE2 preincubation reduced the production of IL-
16 from LLDC by 47, 64, and 65%, at 5, 15, and 25 μg/ml antigen, respectively, compared to 
cells treated with equal amounts of nonspecific human myeloma IgE (Fig. 2B). 
 
Discussion 
 
In this report we demonstrate that FcεRI-induced IL-16 production on LLDC can be inhibited by 
coaggregation with FcγRII. Because human dendritic cells express FcεRI, this was very 
important to demonstrate as the fusion protein GE2 is predicted to interact with these cells in 
addition to mast cells and basophils. 
 
IL-16 is a homotetramer of 14-kDa subunits and plays a role in allergic inflammation. It is 
secreted by a wide range of cells including mast cells and airway epithelial cells [5]. This 
cytokine has been shown to affect many inflammatory mediators such as histamine, regulated 
upon activation, normal T cells expressed and secreted (RANTES), and monocyte chemotactic 
protein-1 (MCP-1) [5]. It is also a potent chemoattractant for CD4+ lymphocytes which are 
important effector cells during the late phase of allergic inflammation. Studies also suggest that 
IL-16 may contribute to the pathogenesis of allergic asthma through the production of allergen-
specific IgE, recruitment of inflammatory cells to the lung, and induction of airway 
hyperresponsiveness [9], [10], [11]. Preventing its release from cells resident in the skin and lung 
is likely to be beneficial in the treatment of allergic inflammation, especially in atopic 
eczema/dermatitis syndrome (AEDS) [12], [13], allergic rhinitis [14], and asthma [11]. 
 
Atopic dermititis (AD) is a common inflammatory skin disease characterized by cutaneous skin 
lesions containing increased numbers of LC. It is common for children with the disease to 
develop asthma and/or allergic rhinitis later in life [15]. A link between allergen exposure and 
AD is suggested based on several observations. First, many AD patients exhibit similar 
immunological findings as allergic rhinitis and asthma patients including increased serum and 
allergen-specific IgE [16]. Second, food allergies can exacerbate skin rashes in a subset of 
patients with AD [17]. Third, AD patients challenged with aeroallergens, either by inhalation or 
epicutaneously, often develop pruritis and eczematoid skin lesions [18], [19], [20]. Fourth, the 
LC present in AD skin lesions overexpress FcεRI which can be activated by IgE-mediated 
crosslinking and uptake antigen through IgE [21], [22], [23]. Lastly, it has been recently shown 
that topical exposure to peanut allergen is a risk factor for the development of generalized peanut 
allergy [24] while epicutaneous sensitization with natural rubber latex induces T helper 2-
dominated dermal inflammation and a strong IgE response in a murine model of natural rubber 
latex-induced, protein contact dermatitis [25]. Therefore, these studies indicate that IgE–FcεR-
mediated mechanisms may play a role in AD and suggest a link between generalized allergic 
sensitization and AD. 
 
A current hypothesis proposes that FcεRI on LC is used to present Ag through the uptake of IgE–
Ag complexes resulting in allergen-specific T-cell responses that lead to further IgE production 
and the late-phase response characteristic of delayed-type hypersensitivity (DTH) [21], [22]. 
Indeed, some AD patients present DTH-like lesions when using the atopy patch test where 
antigen is injected in the skin [26]. However, similar to LC, human mast cells express MHC 
class II, can present antigen, and activate CD4+ T cells [27]. Thus, it is not clear what 
mechanisms lead to the characteristic recruitment of T cells into AD lesions. Nonetheless, GE2 
could potentially interfere with the uptake of IgE antigen by blocking FcεRI antigen presentation 
capabilities. We are currently investigating this hypothesis. 
 
Initially we showed that the human bifunctional Fcε– Fcγ fusion was capable of inhibiting in 
vivo rodent mast cell and in vitro human basophil functional responses [3]. Subsequently, we 
have demonstrated that GE2 can specifically inhibit IgE production by human B cells (Yamada 
et al., J. Biol. Chem., in press) as well as functional and biochemical responses from human mast 
cells (Kepley et al., submitted). We have now shown that this approach using the Fc domain of 
IgE to target and downregulate inflammatory mediator release from FcεRI-positive cells may 
have beneficial effects on later phases of allergic responses-mediated cells other than mast cells 
and basophils. This finding increases the potential of GE2 to be used therapeutically in the 
treatment of human allergic disorders. 
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